Phreesia, Inc. (NYSE:PHR) General Counsel Allison C. Hoffman Sells 1,213 Shares

Phreesia, Inc. (NYSE:PHR) General Counsel Allison C. Hoffman sold 1,213 shares of the company’s stock in a transaction dated Wednesday, April 16th. The stock was sold at an average price of $23.81, for a total value of $28,881.53. Following the completion of the transaction, the general counsel now directly owns 137,921 shares of the company’s stock, valued at approximately $3,283,899.01. The trade was a 0.87 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Phreesia Trading Up 0.1 %

NYSE:PHR opened at $23.92 on Friday. The firm has a fifty day simple moving average of $26.07 and a two-hundred day simple moving average of $24.29. Phreesia, Inc. has a 12 month low of $17.07 and a 12 month high of $30.53. The stock has a market capitalization of $1.41 billion, a price-to-earnings ratio of -16.27 and a beta of 0.82. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.04.

Institutional Trading of Phreesia

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PHR. Johnson Financial Group Inc. boosted its holdings in Phreesia by 381.3% in the fourth quarter. Johnson Financial Group Inc. now owns 1,131 shares of the company’s stock worth $28,000 after acquiring an additional 896 shares in the last quarter. R Squared Ltd bought a new position in shares of Phreesia in the 4th quarter worth $30,000. BankPlus Trust Department acquired a new stake in Phreesia in the 4th quarter valued at $34,000. Quarry LP increased its stake in Phreesia by 210.9% during the 4th quarter. Quarry LP now owns 2,835 shares of the company’s stock valued at $71,000 after purchasing an additional 1,923 shares in the last quarter. Finally, Venturi Wealth Management LLC acquired a new position in Phreesia during the fourth quarter worth $76,000. 92.10% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on PHR. KeyCorp dropped their price objective on shares of Phreesia from $30.00 to $28.00 and set an “overweight” rating for the company in a report on Wednesday. Piper Sandler restated an “overweight” rating and issued a $33.00 price objective (up from $31.00) on shares of Phreesia in a report on Wednesday, January 29th. Canaccord Genuity Group lifted their target price on Phreesia from $34.00 to $35.00 and gave the stock a “buy” rating in a report on Thursday, March 13th. Citigroup raised their price objective on Phreesia from $31.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, January 10th. Finally, DA Davidson decreased their target price on shares of Phreesia from $36.00 to $34.00 and set a “buy” rating for the company in a research report on Monday, April 14th. Twelve equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $31.33.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.